Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ99MR)

This product GTTS-WQ99MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ99MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14829MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ12276MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ5951MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ4979MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ8216MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ10683MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ6502MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ7032MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Fab C225
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW